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Abstract
Introduction—The National Cancer Institute’s (NCI) Community Clinical Oncology Program
(CCOP) contributes one third of NCI treatment trial enrollment (“accrual”) and most cancer
prevention and control (CP/C) trial enrollment. Prior research indicated that the local clinical
environment influenced CCOP accrual performance during the 1990s. As the NCI seeks to
improve the operations of the clinical trials system following critical reports by the Institute of
Medicine and the NCI Operational Efficiency Working Group, the current relevance of the local
environmental context on accrual performance is unknown.
Materials and methods—This longitudinal quasi-experimental study used panel data on 45
CCOPs nationally for years 2000–2007. Multivariable models examine organizational, research
network, and environmental factors associated with accrual to treatment trials, CP/C trials, and
trials overall.
Results—For total trial accrual and treatment trial accrual, the number of active CCOP
physicians and the number of trials were associated with CCOP performance. Factors differ for
CP/C trials. CCOPs in areas with fewer medical school-affiliated hospitals had greater treatment
trial accrual.
Conclusions—Findings suggest a shift in the relevance of the clinical environment since the
1990s, as well as changes in CCOP structure associated with accrual performance. Rather than a
limited number of physicians being responsible for the preponderance of trial accrual, there is a
trend toward accrual among a larger number of physicians each accruing relatively fewer patients
to trial. Understanding this dynamic in the context of CCOP efficiency may inform and strengthen
CCOP organization and physician practice.
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1. Introduction
We stand on the edge of a new era in cancer clinical research. Rapid advances in proteomics
and genomics are reshaping not only the practice of clinical cancer care, but also clinical
research itself [1]. Simultaneously, there is a new imperative on improving the efficiency
and productivity of the national cancer clinical trials system. The Institute of Medicine
(IOM) and the National Cancer Institute’s (NCI’s) Operational Efficiency Working Group
(OEWG) have recently issued stark reports advocating for substantial change in the cancer
clinical trials system, which has reached “a state of crisis [2–4].” Cancer research leaders
recently reiterated this urgency at the NCI-American Society of Clinical Oncology (ASCO)
symposium, and specifically emphasized better understanding of the drivers of research
efficiency and productivity [5].
To date, the NCI Cooperative groups that develop and manage NCI clinical trials have been
a focal point of emphasis, and the IOM and OEWG reports have catalyzed their massive
reorganization, consolidating from 9 groups to 4 with substantial corresponding system
changes [6]. However, 30% of NCI treatment trial accrual and nearly all of its cancer
prevention and control (CP/C) trial accrual (over 28,000 accruals in 2007) comes from the
NCI Community Clinical Oncology Program (CCOP). The CCOP is tightly connected to the
Cooperative groups; however, it is still independent of them, and while efforts to restructure
the cooperative groups will affect CCOPs, research shows that organizational characteristics
and local market conditions significantly influence CCOP productivity. For example, studies
of CCOP performance in the 1990s demonstrated that managed care penetration and hospital
competition were relevant factors affecting trial accrual, and that accrual to treatment trials
and CP/C trials were differently affected by not only these factors, but also CCOP
organizational characteristics [7–9] (Fig. 1).
Much has changed since the 1990s. The clinical practice dynamic surrounding managed care
is no longer what it was, and other factors have arisen and changed the clinical environment
in which CCOPs operate. Among them, the Medicare Modernization Act of 2003 changed
the reimbursement landscape substantially for cancer care, especially for chemotherapy,
which is a dominant focus of investigation in NCI clinical trials [10,11]. These changes have
spawned concerns regarding consequent changes in patient access and referral, which may
also affect clinical trials participation [12]. As the nation engages in historic health care
reform accompanied by substantial uncertainty [13,14], the current effect of the healthcare
environment on NCI clinical trials is unknown.
This study reexamines the NCI CCOPs to inform and update our understanding of factors
associated with trial enrollment and program sustainability. It employs a multilevel approach
to examine factors associated with the CCOP, NCI research network, and local clinical care
environment to understand factors associated with treatment trial accrual, CP/C trial accrual,
and total trial accrual in the past 10 years. In doing so, this study addresses the calls from the
IOM and NCI/ASCO to develop a better understanding of the drivers of clinical trial
productivity and efficiency in the context of the clinical provider community in which
cancer care is delivered.
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2. Materials and methods
2.1. The NCI CCOP Program
This study focuses on the NCI CCOP program, which has been described extensively
elsewhere [1,15]. Briefly, the CCOP is a nationwide provider-based research network
(PBRN) enabling community physicians to participate in NCI clinical research not only by
enrolling patients in trials, but also by engaging them with academic researchers to
contribute practice-based practical insight to collaboratively develop practical studies. The
CCOP goals include not only enrolling patients onto trials, but also accelerating the use of
evidence-based medicine in the community. Through first-hand participation in the clinical
trials, community physicians practice the state-of-the-art science being investigated through
the trial, and develop a sense of ownership and acceptance of study findings. This
strengthens their likelihood of acting on the research findings and incorporating the
evidence-based medicine into practice. Recent studies have validated this NCI goal, by
showing that organizational participation in NCI clinical research is positively associated
with adoption of state-of-the-art care [16–18] (Fig. 2).
2.2. Data and sample
This single-group, longitudinal quasi-experimental study used yearly panel data from 2000
to 2007 collected from CCOP progress reports and the NCI’s CCOP, MBCCOP, and
Research Base Management System. The unit of analysis was the CCOP. Because healthcare
environmental data were measured at the metropolitan statistical area (MSA), we included
all CCOPs that served at least one MSA and were active in the year 2000. This resulted in
45 CCOPs in the year 2000 decreasing to 41 CCOPs in 2007, for a total of 355 CCOP-year
observations in the analytic sample.
Three dependent variables were separately examined as markers of CCOP performance:
treatment trial accrual, CP/C trial accrual, and total trial accrual. Independent variables
included CCOP characteristics, CCOP-Research Base (RB)1 network characteristics, and
environmental characteristics. Among CCOP characteristics, we examined the number of
active and enrolling CCOP physicians, the number of CCOP components, the number of
active institutional review boards (IRBs), and the number of CCOP or RB meetings attended
by CCOP physicians or staff. A gini index was developed to enumerate each CCOP site’s
accrual as being concentrated among a few CCOP physicians, or more broadly and evenly
distributed among multiple physicians. [19] This index was used to create a categorical
variable indicating low, medium, and high physician accrual equity. The CCOP-RB network
characteristics included the number of affiliated RBs and the number of treatment trials, CP/
C trials, and total trials for which the CCOP had at least one accrual during the year.
To measure environmental characteristics, we used managed care penetration, hospital
competition, and clinical trials competition. Using the InterStudy Competitive Edge
Regional Market Analysis dataset, managed care penetration was measured as health
maintenance organization (HMO) penetration for each CCOP’s MSA [20]. HMO
penetration was calculated by dividing the number of HMO enrollees in the MSA by its total
population. For hospital competition, we used the American Hospital Association (AHA)
Survey Database to calculate the Herfindahl–Hirschman Index (HHI) for each MSA, based
on each short-term acute care hospital’s total number of admissions divided by the total of
all admissions in the MSA, then squared and summed [21]. The final measure was
calculated as one minus the HHI. Data from the Area Resource File were used to develop a
1NCI Research Bases include the NCI Cooperative Groups and four other NCI affiliated organizations that develop and manage
clinical trials conducted through the NCI research networks.
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measure of clinical trials availability or competition in the MSA, and measured as the
proportion of hospitals in the MSA that were unaffiliated with medical schools. Additional
environmental control variables included the proportion of the MSA that was insured, and
whether or not the state had a legislative mandate that regular care be covered by insurance
for those enrolled in clinical trials [22].
Although the study captured data on nearly all CCOPs, the total sample size called for using
a limited set of variables to conserve degrees of freedom in the multivariable analysis.
Accordingly, informed by annual accrual trends and a review of preliminary regression
analysis, categorical variables indicating the year were collapsed from eight variables to four
reflecting the years 2000–2001, 2002–2003, 2004–2005, 2006–2007. CCOP-level data were
linked to MSA-level data based on the MSA in which the CCOP headquarter was located, as
done previously [7].
The dependent variable was available for all 355 observations, as was the case for nearly all
observations on independent variables. In 2006, HHI was missing for 7 observations at the
MSA level. Because of the high correlation between MSA-level and county-level measures
of HHI (0.829, p>0.001), county-level HHI replaced missing MSA-level values for this year.
For 2007, because of the very high inertia in this measure, observations for HHI were
imputed by linear interpolation/extrapolation based on immediately prior years.
To select the functional form for the dependent variable, we used the Wooldridge test
examining if logged annual accrual was superior to un-logged annual accrual in terms of
overall model fit [23]. To select the functional forms of the independent variables in the
model, we used adjusted R-squared values [23]. We determined that the non-logged annual
accrual model and non-quadratic forms of HMO penetration and hospital competition best
fit the data. Additionally, in order to allow the effect of the number of IRBs on trial accrual
to vary for CCOPs with a higher or lower number of CCOP components, we examined an
interaction term of number of IRBs number of components.
2.3. Analytic model
Using a single-group, longitudinal panel design, we analyzed the three dependent variables
separately in three models. We compared three different types of analytic methods: pooled-
OLS with dummy variables for time, fixed effects, and random effects estimation. A
Hausman test and a Breusch–Pagan Lagrange Multiplier test suggested that fixed effects
estimation for total accrual and treatment accrual, and random effects estimation for the CP/
C accrual model were most appropriate [23,24]. T-tests were used to test the significance of
single variables and F-tests to examine the joint significance categorical constructs in each
of the three models described above. All analyses were performed using Stata 11, and tests
were conducted using a minimum significance level of 0.05 (StataCorp. 2009. Stata
Statistical Software: Release 11. College Station, TX: StataCorp LP).
3. Results
During the period of 2000–2007, the average accrual per CCOP for total trials, treatment
trials and CP/C trials was 240.3, 123.2, and 117.1 patients per year, respectively (Table 1).
The average CCOP had approximately 21 physicians accruing patients to a trial, was
affiliated with slightly less than five cooperative groups, and had accrual to 31 treatment
trials and 13 CP/C trials. Accrual was evenly distributed among the time periods. The
majority of CCOPs (52%) were located in the North Central region of the United States.
Bivariate correlations are presented in Table 2.
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In the total trial accrual model, only the number of active CCOP physicians (p<.009) and the
number of total trials (p<.001) were significant. An increase in either of these factors was
associated with an increase in total clinical trial accrual. The categorical variable indicating
low, medium, and high physician accrual equity was not jointly significant [F(2, 292)=1.0,
Prob>F=0.37]. The marginal effect of Number of IRBs and Number of components (using
the interaction) was not significant in this or any of the other models. The only significant
environmental factor was the categorical variable for proportion of hospitals in MSA with
medical school affiliations [F(2, 292)= 3.3, Prob>F=0.04]; CCOPs in MSAs with fewer
medical school affiliated hospitals were associated with higher total trial accrual.
In the treatment accrual model, the number of active CCOP physicians (p<.001) and the
number of treatment trials (p<.001) were significantly associated with greater treatment trial
accrual. The categorical variable indicating low, medium, and high physician accrual equity
was jointly significant [F(2, 292)=3.1, Prob>F=0.047]. In this model, lower accrual equity
among physicians (i.e., the majority of accrual concentrated among few physicians) was
generally associated with higher treatment trial accrual, though this association was not
consistently statistically significant. Similar to the total accrual model, the CCOPs in MSAs
with fewer medical school affiliated hospitals were significantly associated with greater
treatment trial accrual [F(2, 292)=3.1, Prob>F=0. 047].
In the CP/C model, the number of CP/C trials (p<.001) and RB affiliations (p<.028) was
again significantly associated with greater total trial accrual. Unlike the treatment trial
accrual model, higher accrual equity among physicians was generally associated with higher
CP/C trial accrual; however, this was not statistically significant. Hospital competition was
significantly associated with a decrease in CP/C trial accrual (p<0.039). All other variables
and constructs were statistically insignificant (Table 3).
4. Discussion
This study examined the organizational and environmental characteristics associated with
accrual in the NCI’s CCOP program. One of the most striking findings in the analysis may
be that, compared with analyses of the prior decade [7], very few traditionally-measured
CCOP organizational or environmental characteristics remain associated with CCOP accrual
performance. A hallmark of the CCOP has been its long history of performance data
collection and a philosophy of systematic self-examination to inform continuous
improvement [1,7–9,25,26]. As the CCOP continues to embrace this philosophy and engage
in strategic planning efforts, also incorporating guidance from the recent IOM and OEWG
[3,4], one of its most important priorities may be to examine new measures associated with
organizational performance and implement them to augment the set of measures it currently
collects.
Interpreting the results of this analysis in the context of prior research, we see current
CCOPs experiencing higher per-CCOP accrual in current years, suggesting greater
efficiencies in operation than before. The CCOPs had a comparable number of CP/C trials
open, though substantially fewer treatment trials open compared to the 1990s. Given this
trend, it may be the case that funding previously allocated to administrative staff for opening
and processing trials may have been reallocated to fund more staff that enrolled or helped
manage patients on trials, and thus be a key driver of the apparent accrual efficiencies.
CCOPs in the 2000s tended to be larger and have a slightly greater number of accruing
physicians than those in the 1990s, further suggesting that achieving a “critical mass” may
be associated with CCOP success. This may be through greater programmatic stability (i.e.,
better able to absorb individual physicians coming and going) or broader access to additional
funding from affiliated hospitals and clinical programs. Alternatively, it may offer enhanced
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access to a greater number of patients or a more diverse patient population. This may also be
reflected in CCOPs recently being affiliated with a greater number of Research Bases than
before, with associated access to a more diverse set of clinical trials from which to choose to
meet the needs of the more diverse population.
The non-significance of HMO penetration and hospital competition suggests that CCOPs
able to adapt to the disruptive changes in healthcare financing seen in the 1980s and 1990s
were more likely to survive and thrive in the 2000s. It may also indicate that the once-
volatile market characteristics are in fact less disruptive than they once were.
For CP/C accrual, surprisingly few factors are strongly predictive of performance compared
to those associated with either CP/C in the 1990s or with treatment accrual in the 2000s.
Another notable contrast is the physician accrual profile, in which treatment trial
performance appears to have favored few physicians who were responsible for most accrual,
compared to a broader set of physicians with more equal accrual among CP/C trials.
Comparing CP/C and treatment models further, statistical specification tests suggested that a
different model (Random Effects estimation) had a better fit for CP/C compared to treatment
(Fixed Effects estimation). Together, these points jointly suggest that factors associated with
CP/C accrual performance are fundamentally different from those associated with treatment
accrual. In practical terms, this observation reflects the reality of CCOP operations and is
quite logical, as treatment accrual tends to take place in oncology practices while CP/C
accrual commonly takes place in a much broader set of clinical as well as non-clinical
settings. Therefore, it makes sense that organizational and environmental factors associated
with oncology treatment may differently affect accrual to treatment trials compared to
accrual to CP/C trials, for example, in primary care practices, follow-up clinics, or the
broader non-clinical community.
Study findings suggest that, more so than clinical competition, there may be academic
competition. Specifically, there tends to be less accrual among CCOPs in communities with
a stronger academic presence vis-à-vis the proportion of hospitals affiliated with a medical
school. It may be that patients who would contemplate enrollment in a clinical trial would be
likely to accept referral or self-refer to an academic center, rather than refer to a CCOP
practice. On one hand, this speaks to the CCOP’s strategic priority focus outside of the
academic medical centers, and the establishment of local CCOPs in communities that do not
have a medical school. Conversely, it may be that CCOPs in communities with a strong
academic presence are functionally different from other CCOPs either in terms of their
structure, the trials they offer, the strength or consistency of referral relationships, or the
different practice focus and priorities of CCOP practitioners in these communities. Again,
we look at the trend toward greater treatment trial accrual among CCOPs with low accrual
equity physicians (i.e., a small proportion of physicians have a preponderance of accrual).
There are several possible causes of this phenomenon. CCOP physicians in communities
where there is an academic presence may feel greater pressure to more broadly serve the
practice organization’s many missions, rather than “specialize” in clinical research. This
may contrast to communities without academic centers, where the CCOP may be the only
source of clinical trial participation, and thus functionally serve as “the academic center” for
that community, in turn promoting cultural norms that encourage specialization in different
areas among professionals — clinical care, research, and others. Additionally, this finding
may indicate that a dynamic, motivated physician may provide a bolus in trial enrollment. It
may also suggest that small practices with a strong focus on trial enrollment may outperform
their larger peer practices. Further research should examine these issues, as understanding
them may inform CCOP organization and physician practice focus, and strengthen those
CCOPs operating in both academic and non-academic communities.
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Among study limitations, our study involves a sample of only 45 CCOPs followed for eight
years. Though this represents nearly all CCOPs, it is a small sample to examine with fixed
effects and random effects estimation, and close attention must be paid to balance sufficient
model specification with a need for erring on the side of parsimony in terms of degrees of
freedom. A tradeoff of being parsimonious is that this minimally-specified model may suffer
from excluding relevant variables. This study examined the variables collected by CCOPs
that were most relevant and incorporated additional measures. However, there may be other
environmental and organizational factors or patient population, physician, hospital and
clinical trial specific characteristics that may have had an effect on clinical trial accrual for
which our model did not control. If these factors truly belonged in the model, omitting them
will result in biased estimates. As the CCOP goes forward to identify additional relevant
variables, understanding the relative strength of relevance for each will be important.
Among other issues, many of our environmental variables are linked to the CCOPs by the
MSA where the CCOP headquarters is located, which is suboptimal because some CCOPs
are active in more than one MSA. In these instances, variables such as hospital competition
or HMO penetration might not comprehensively reflect the environment in which the CCOP
actually operates. However, most CCOPs operate in a limited region, and for this study
sample, there was limited variation with these regions, and thus limited risk of bias due to
this measurement method. In this study, hospital competition was based on the number of
hospital admissions; given the outpatient nature of the majority of cancer care, it may be
more relevant to measure hospital competition differently in the future. Finally, physician
competition was measured using the number of practicing physicians in the MSA. Given
that this study focuses on clinical trials for cancer patients, it may have been more accurate
to reflect physician competition in terms of practicing oncologists in the MSA or CCOP
service area. This data was not available for this study.
5. Conclusions
More so than any one organizational or environmental characteristic, the flexibility of
CCOPs and the motivation of their research community have been central aspects enabling a
great number of CCOPs to succeed [1]; CCOPs that stopped operations may have done so in
part because they were unable to adapt on the local level to the changing environments
around them. The CCOP’s consistent history of self-examination has fueled both its
flexibility and success. Moving forward, as the CCOP continues its strategic planning, it will
be important to understand factors that drive performance and to systematically identify
measures allowing these factors to be monitored over time, to provide ongoing feedback and
inform the performance and success of local CCOPs. The successes of CCOP and PBRNs
like it that reach broadly into the community are of increasing importance as development of
effective treatments for all populations increasingly demands access to heterogeneous
populations for research. Accordingly, understanding factors relevant to PBRN success will
continue to be of great importance. This knowledge will thus inform the National Institutes
of Health Roadmap and be responsive to the IOM, NCI, and NCI/ASCO as the CCOP
pursues its goals of accelerating the pace of scientific discovery, while facilitating the
translation of evidence-based research into practice.
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Overall new accruals to NCI trials: NCI CCOP vs. NCI non-CCOP accrual, 2000–2007.
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Treatment and CP/C trial accrual in the NCI CCOP Program.
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Table 1
Descriptive characteristics of the CCOP analytic sample.
Variable Mean (Std. dev.) [Range]
Performance variables
Total accrual 240.28 (160.12) [4–1027]
CP/C accrual 123.22 (76.55) [0–733]
Treatment accrual 117.06 (102.11) [0–508]
CCOP characteristics
Num. of active CCOP MDs 21.35 (14.96) [0–96]
Num. of CCOP components 6.60 (5.25) [0–29]
Num. of active IRBs 2.93 (3.07) [1–19]
Num. of CCOP or RB meetings attended 29.22 (39.30) [0–281]
Low physician accrual equity 0.36 (0.48) [0–1]
Medium physician accrual equity 0.38 (0.49) [0–1]
High physician accrual equity 0.26 (0.44) [0–1]
CCOP-RB network characteristics
Num. of affiliated RBs 4.93 (2.54) [0–10]
Num. of total trials 43.95 (19.78) [5–120]
Num. of treatment trials 30.97 (14.69) [1–85]
Num. of CP/C trials 12.98 (6.37) [1–40]
Environmental characteristics
Hospital competition (1-HHI) 0.79 (0.15) [0.45–0.98]
HMO penetration 0.22 (0.12) [0.01–0.64]
Proportion of MSA uninsured 0.13 (0.04) [0.07–0.33]
High proportion of hospitals in MSA with medical school affiliation 0.34 (0.48) [0–1]
Medium proportion of hospitals in MSA with medical school affiliation 0.34 (0.47) [0–1]
Low proportion of hospitals with in MSA medical school affiliation 0.32 (0.47) [0–1]
State insurance mandate 0.26 (0.44) [0–1]





Region (mean n, % of sample in each region)
Northeast 0.0 (0.0%)
Mid-Atlantic Region 4.9 (11.0%)
East North Central Region 13.0 (29.3%)
West North Central Region 9.9 (22.3%)
South Atlantic Region 5.0 (11.3%)
East South Central Region 0.0 (0.0%)
West South Central Region 3.0 (6.8%)
Mountain Region 3.6 (8.2%)
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Variable Mean (Std. dev.) [Range]
Pacific Region 5.0 (11.3%)
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